Charles River Laboratories International, Inc. (CRL): Capital Expenditures
$219.15M
Year ended 2025-12-27
$211.54M
Trailing 12 months to 2026-06-27
-12.3%
3-year compound annual growth
+5.6%
5-year compound annual growth
+13.2%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-27 | $219.15M | -5.9% | 2026-02-18, From 2024-12-29 |
| 2024-12-28 | $232.97M | -26.9% | 2026-02-18, From 2023-12-31 |
| 2023-12-30 | $318.53M | -1.9% | 2026-02-18, From 2023-01-01 |
| 2022-12-31 | $324.73M | +41.9% | 2025-02-19, From 2021-12-26 |
| 2021-12-25 | $228.77M | +37.4% | 2024-02-14, From 2020-12-27 |
| 2020-12-26 | $166.56M | +18.5% | 2023-02-22, From 2019-12-29 |
| 2019-12-28 | $140.51M | +0.3% | 2022-02-16, From 2018-12-30 |
| 2018-12-29 | $140.05M | +69.9% | 2021-02-17, From 2017-12-31 |
| 2017-12-30 | $82.43M | +49.1% | 2020-02-11, From 2017-01-01 |
| 2016-12-31 | $55.29M | -12.6% | 2019-02-13, From 2015-12-27 |
| 2015-12-26 | $63.25M | +11.1% | 2018-02-13, From 2014-12-28 |
| 2014-12-27 | $56.92M | +45.4% | 2017-02-14, From 2013-12-29 |
| 2013-12-28 | $39.15M | -17.6% | 2016-02-12, From 2012-12-30 |
| 2012-12-29 | $47.53M | -3.3% | 2015-02-17, From 2012-01-01 |
| 2011-12-31 | $49.14M | +14.7% | 2014-02-25, From 2010-12-26 |
| 2010-12-25 | $42.86M | -46.3% | 2013-02-27, From 2009-12-27 |
| 2009-12-26 | $79.85M | -59.8% | 2012-02-27, From 2008-12-28 |
| 2008-12-27 | $198.64M | n/a | 2011-02-23, From 2007-12-30 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Charles River Laboratories International, Inc. (CRL) | 2025-12-27 | $219.15M | -5.9% |
| Medpace Holdings, Inc. (MEDP) | 2025-12-31 | $31.36M | -14.2% |
| Icon PLC (ICLR) | 2025-12-31 | $174.21M | +3.7% |
| Iqvia Holdings Inc. (IQV) | 2025-12-31 | $603.00M | +0.2% |
| NRC Health (NRC) | 2025-12-31 | $10.71M | -30.7% |
| MaxCyte, Inc. (MXCT) | 2025-12-31 | $1.77M | +7.1% |
| OmniAb, Inc. (OABI) | 2025-12-31 | $565.0K | -69.9% |
| Foxo Technologies Inc. (FOXO) | 2025-12-31 | $62.0K | n/a |
| bioAffinity Technologies, Inc. (BIAF) | 2025-12-31 | $60.6K | -23.4% |
Compare CRL, MEDP, ICLR, IQV side by side · Screen every company in Services-Commercial Physical & Biological Research ↗